Amiortrophic Lateral Sclerosis
Seminar
Amyotrophic lateral sclerosis
Matthew C Kiernan, Steve Vucic, Benjamin C Cheah, Martin R Turner, Andrew Eisen, Orla Hardiman, James R Burrell, Margaret C Zoing
Lancet 2011; 377: 942–55
Published Online
February 7, 2011
DOI:10.1016/S01406736(10)61156-7
Neuroscience Research
Australia and Prince of Wales
Clinical School, University of
New South Wales, Sydney,
Australia (Prof M C Kiernan DSc,
B C Cheah MBiostat,
J Burrell MBBS, M C Zoing BNurs);
Western Clinical School,
University of Sydney, Sydney,
Australia (S Vucic PhD); Nuffield
Department of Clinical
Neurosciences, University of Oxford, Oxford, UK
(M R Turner PhD); Division of
Neurology, Department of
Medicine, University of British
Columbia Vancouver,
Vancouver, Canada
(Prof A Eisen MD); and
Trinity College Institute of
Neuroscience, Dublin, Ireland
(Prof O Hardiman MD)
Correspondence to:
Prof Matthew C Kiernan,
Neuroscience Research Australia,
Barker Street, Randwick, Sydney,
NSW 2031 Australia
m.kiernan@unsw.edu.au
Amyotrophic lateral sclerosis (ALS) is an idiopathic, fatal neurodegenerative disease of the human motor system. In this Seminar, we summarise current concepts about the origin of the disease, what predisposes patients to develop the disorder, and discuss why all cases of ALS are not the same. In the 150 years since Charcot originally described
ALS, painfully slow progress has been made towards answering these questions. We focus on what is known about
ALS and where research is heading—from the small steps of extending longevity, improving therapies, undertaking clinical trials, and compiling population registries to the overarching goals of establishing the measures that guard against onset and finding the triggers for this neurodegenerative disorder.
Introduction
Since the 1990s, there has been growing scientific and clinical interest in amyotrophic lateral sclerosis (ALS).
Advances in our understanding of the glutamate
neurotransmitter
Amyotrophic lateral sclerosis
Matthew C Kiernan, Steve Vucic, Benjamin C Cheah, Martin R Turner, Andrew Eisen, Orla Hardiman, James R Burrell, Margaret C Zoing
Lancet 2011; 377: 942–55
Published Online
February 7, 2011
DOI:10.1016/S01406736(10)61156-7
Neuroscience Research
Australia and Prince of Wales
Clinical School, University of
New South Wales, Sydney,
Australia (Prof M C Kiernan DSc,
B C Cheah MBiostat,
J Burrell MBBS, M C Zoing BNurs);
Western Clinical School,
University of Sydney, Sydney,
Australia (S Vucic PhD); Nuffield
Department of Clinical
Neurosciences, University of Oxford, Oxford, UK
(M R Turner PhD); Division of
Neurology, Department of
Medicine, University of British
Columbia Vancouver,
Vancouver, Canada
(Prof A Eisen MD); and
Trinity College Institute of
Neuroscience, Dublin, Ireland
(Prof O Hardiman MD)
Correspondence to:
Prof Matthew C Kiernan,
Neuroscience Research Australia,
Barker Street, Randwick, Sydney,
NSW 2031 Australia
m.kiernan@unsw.edu.au
Amyotrophic lateral sclerosis (ALS) is an idiopathic, fatal neurodegenerative disease of the human motor system. In this Seminar, we summarise current concepts about the origin of the disease, what predisposes patients to develop the disorder, and discuss why all cases of ALS are not the same. In the 150 years since Charcot originally described
ALS, painfully slow progress has been made towards answering these questions. We focus on what is known about
ALS and where research is heading—from the small steps of extending longevity, improving therapies, undertaking clinical trials, and compiling population registries to the overarching goals of establishing the measures that guard against onset and finding the triggers for this neurodegenerative disorder.
Introduction
Since the 1990s, there has been growing scientific and clinical interest in amyotrophic lateral sclerosis (ALS).
Advances in our understanding of the glutamate
neurotransmitter
References: www.thelancet.com Vol 377 March 12, 2011 Seminar